Innovation and Technology
From Singapore

MiRXES Hong Kong Limited

Founded in 2014, MiRXES is a Singapore-headquartered biotechnology company focusing on improving and saving lives with ribonucleic acid (RNA)-powered disease early detection tests, and operates in Mainland China, Japan, the US and Hong Kong, with commercial activities in over 45 countries globally.

Its founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA) in the early 2000s, and brought its technology from laboratory to clinic.

In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, breast, pancreatic and ovarian cancers.

The company believes that the future of healthcare will shift from treatment to prevention, and is committed to benefiting the public by delivering preventive healthcare solutions via its science and innovation.

11.03.2022
BioTech, HealthCare
https://mirxes.com
11.03.2022
Contact Us
Leave your details and we'll be in touch.

The personal information you have provided will help us deliver, develop and promote our services. By submitting your details, ticking the boxes and clicking "Submit" indicate that you have read and agreed to our privacy policy and cookie policy. Please read these to understand your data rights.